JP2016514727A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514727A5
JP2016514727A5 JP2016504377A JP2016504377A JP2016514727A5 JP 2016514727 A5 JP2016514727 A5 JP 2016514727A5 JP 2016504377 A JP2016504377 A JP 2016504377A JP 2016504377 A JP2016504377 A JP 2016504377A JP 2016514727 A5 JP2016514727 A5 JP 2016514727A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016504377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514727A (ja
JP6360881B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/031442 external-priority patent/WO2014153509A1/en
Publication of JP2016514727A publication Critical patent/JP2016514727A/ja
Publication of JP2016514727A5 publication Critical patent/JP2016514727A5/ja
Application granted granted Critical
Publication of JP6360881B2 publication Critical patent/JP6360881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016504377A 2013-03-22 2014-03-21 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ Active JP6360881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804314P 2013-03-22 2013-03-22
US61/804,314 2013-03-22
PCT/US2014/031442 WO2014153509A1 (en) 2013-03-22 2014-03-21 Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase

Publications (3)

Publication Number Publication Date
JP2016514727A JP2016514727A (ja) 2016-05-23
JP2016514727A5 true JP2016514727A5 (https=) 2017-04-27
JP6360881B2 JP6360881B2 (ja) 2018-07-18

Family

ID=51581522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504377A Active JP6360881B2 (ja) 2013-03-22 2014-03-21 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ

Country Status (6)

Country Link
US (2) US9724354B2 (https=)
EP (1) EP2976086B1 (https=)
JP (1) JP6360881B2 (https=)
CN (1) CN105209042B (https=)
CA (1) CA2907726A1 (https=)
WO (1) WO2014153509A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061437T2 (hu) * 2015-10-23 2023-06-28 Navitor Pharm Inc A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
LT3442535T (lt) 2016-04-15 2022-10-25 Cancer Research Technology Limited Heterocikliniai junginiai kaip ret kinazės inhibitoriai
DK3442980T3 (da) 2016-04-15 2021-08-30 Cancer Research Tech Ltd Heterocykliske forbindelser som ret-kinase-hæmmere
ITUA20164278A1 (it) * 2016-06-10 2017-12-10 International Soc For Drug Development S R L COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
WO2022104206A1 (en) * 2020-11-13 2022-05-19 Neuron23, Inc. Kinase modulators and methods of use thereof
CN112782402A (zh) * 2020-12-11 2021-05-11 南京市儿童医院 一种利用mk-5108阻断aurka来减轻肾纤维化的方法

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
ES2150113T3 (es) 1995-04-03 2000-11-16 Novartis Ag Derivados de pirazol y procedimientos para la preparacion de los mismos.
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
KR19990087585A (ko) 1996-03-08 1999-12-27 돈 리사 로얄 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
AU755062B2 (en) 1997-02-07 2002-12-05 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6251689B1 (en) 1998-05-14 2001-06-26 Telik, Inc. Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof
YU76100A (sh) 1998-06-02 2003-12-31 Osi Pharmaceuticals Inc. Pirolo(2,3-d) pirimidin preparati i njihova primena
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
TR200101359T2 (tr) 1998-11-16 2001-11-21 Basf Aktiengesellschaft 3-[Benz(Ok/Otı)Azol-7-İl]-1H-Pirimidin-2,4-Dionlar
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CN100389825C (zh) 1999-08-11 2008-05-28 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001072299A1 (en) 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
WO2003082341A1 (en) 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Hsp90-저해제로서의 신규 헤테로시클릭 화합물
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
AU2005219517A1 (en) 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
KR100843526B1 (ko) 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
MX2007013065A (es) 2005-04-22 2008-01-14 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
AU2006283945A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
RU2008110941A (ru) 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2624220A1 (en) 2005-09-29 2007-04-12 Wyeth 1- (1h- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP2009520028A (ja) 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Igfr抑制剤および抗癌剤の併用
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
BRPI0708615A2 (pt) 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
EP2004683B1 (en) 2006-03-24 2016-05-11 Biogen Hemophilia Inc. Pc5 as a factor ix propeptide processing enzyme
CA2647543A1 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
DE102006020327A1 (de) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
CA2656393A1 (en) 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
EP2046292B1 (en) 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP1900729A1 (en) 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
EP2077850A2 (en) 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
UY31292A1 (es) 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
CA2716334A1 (en) 2007-11-13 2009-05-22 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン, エルエルシー キナーゼインヒビターおよび使用方法
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
RU2535032C2 (ru) * 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
WO2010144468A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
ES2432315T3 (es) 2009-08-28 2013-12-02 Takeda Pharmaceutical Company Limited Compuestos de hexahidrooxazinopterina para su uso como inhibidores de mTOR
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2016514727A5 (https=)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2015500884A5 (https=)
JP2014503574A5 (https=)
JP2015532295A5 (https=)
JP2015511638A5 (https=)
JP2019502763A5 (https=)
JP2015520143A5 (https=)
JP2019500352A5 (https=)
JP2020514311A5 (https=)
JP2014500295A5 (https=)
RU2016134751A (ru) Соединения
JP2017524702A5 (https=)
JP2014513138A5 (https=)
JP2016509047A5 (https=)
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
MX379459B (es) Inhibidores de bromodominios.
JP2012513390A5 (https=)
JP2016518437A5 (https=)
RU2015124002A (ru) Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
JP2017527532A5 (https=)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2016513696A5 (https=)
JP2016515628A5 (https=)